>
LOW Cost DIY Self Watering Raised Garden Wicking Bed From an IBC
Big NAS, Lil NAS (moving 13) (Network-Attached Storage)
I Built an Atmosphere Powered Battery...
I SAVED THOUSANDS $$$ NOT USING ZIP SYSTEM
The first reverse microwave in the U.S.: you can have it at home to save energy while cooking
BREAKTHROUGH : Lightsolver Makes Ultrafast Laser Based Computers
$300,000 robotic micro-factories pump out custom-designed homes
$300,000 robotic micro-factories pump out custom-designed homes
Skynet Has Arrived: Google Follows Apple, Activates Worldwide Bluetooth LE Mesh Network
The Car Fueled Entirely by the Sun Takes Huge Step Towards Production
A new wave of wearable devices will collect a mountain on information on us...
Star Trek's Holodeck becomes reality thanks to ChatGPT and video game technology
Blazing bits transmitted 4.5 million times faster than broadband
The one-two punch provided by the novel approach could pave the way for earlier detection and more effective treatment of the disease.
With an average five-year survival rate of less than 10%, pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal forms of cancer. It's also difficult to detect using conventional imaging methods, including positron emission tomography (PET) scans.
Now, researchers at Osaka University in Japan have developed a strategy for combatting this deadly cancer by combining therapeutics and diagnostics – 'theranostics' – into a single, integrated process.
The process developed by the researchers uses radioactive monoclonal antibodies (mAb) to target glypican-1 (GPC1), a protein highly expressed in PDAC tumors. GPC1 has been implicated in cancer cell proliferation, invasion, and metastasis, and high expression of the protein is a poor prognostic factor in some cancers, including pancreatic cancer.
"We decided to target GPC1 because it is overexpressed in PDAC but is only present in low levels in normal tissues," said Tadashi Watabe, the study's lead author.
The researchers injected human pancreatic cancer cells into mice, allowing them to develop into a full tumor. The xenograft mice were administered intravenous GPC1 mAb labeled with radioactive zirconium (89Zr) and observed for antitumor effects.
"We monitored 89Zr-GPC1 mAb internalization over seven days with PET scanning," said Kazuya Kabayama, the study's second author. "There was strong uptake of the mAb into the tumors, suggesting that this method could support tumor visualization. We confirmed that this was mediated by its binding to GPC1, as the xenograft model that had GPC1 expression knocked out showed significantly less uptake."